Coagulation Factor Xa (Andexxa) Now Available on EH’s Pharmacy Formulary

The United States Food and Drug Administration (FDA) recently approved coagulation factor Xa (Andexxa) for the reversal of rivaroxaban (Xarelto) or apixaban (Eliquis) when needed due to life-threatening or uncontrolled bleeding. The drug carries a boxed warning of thromboembolic risks, ischemic risks, cardiac arrest, and sudden deaths. The Englewood Health Pharmacy is making its limited […]

Antibiotic Stewardship Update: Restrictions on Fluoroquinolones

The Antibiotic Stewardship team requests your participation in Englewood Hospital’s most recent Antibiotic Stewardship initiative: the restriction for both oral and injectable fluoroquinolones. Fluoroquinolone use (i.e. levofloxacin, ciprofloxacin, moxifloxacin, ofloxacin) has significantly and consistently been associated with the development of Clostridium difficile infections (CDI) and extended-spectrum beta-lactamase Enterobacteriaceae such as E. Coli. There is also […]